AAAAAA

   
Results: 1-8 |
Results: 8
RESULTS OF THE ATORVASTATIN VERSUS REVASCULARIZATION TREATMENTS (AVERT) STUDY - AN 18-MONTH STUDY OF AGGRESSIVE LIPID-LOWERING IN PATIENTS WITH STABLE CORONARY-ARTERY DISEASE INDICATED FOR A CATHETER-BASED REVASCULARIZATION (CR)
Authors: PITT B WATERS D BROWN VW MCCORMICK LS WAGNER B SHURZINSKE L VANBOVEN AJ BLACK DM
Citation: B. Pitt et al., RESULTS OF THE ATORVASTATIN VERSUS REVASCULARIZATION TREATMENTS (AVERT) STUDY - AN 18-MONTH STUDY OF AGGRESSIVE LIPID-LOWERING IN PATIENTS WITH STABLE CORONARY-ARTERY DISEASE INDICATED FOR A CATHETER-BASED REVASCULARIZATION (CR), Circulation, 98(17), 1998, pp. 3342-3342
EFFICACY AND SAFETY OF A NEW HYDROXYMETHYLGLUTARYL-COENZYME A REDUCTASE INHIBITOR, ATORVASTATIN, IN PATIENTS WITH COMBINED HYPERLIPIDEMIA -COMPARISON WITH FENOFIBRATE
Authors: OOI TC HEINONEN T ALAUPOVIC P DAVIGNON J LEITER L LUPIEN PJ SNIDERMAN AD TAN MH TREMBLAY G SORISKY A SHURZINSKE L BLACK DM
Citation: Tc. Ooi et al., EFFICACY AND SAFETY OF A NEW HYDROXYMETHYLGLUTARYL-COENZYME A REDUCTASE INHIBITOR, ATORVASTATIN, IN PATIENTS WITH COMBINED HYPERLIPIDEMIA -COMPARISON WITH FENOFIBRATE, Arteriosclerosis, thrombosis, and vascular biology, 17(9), 1997, pp. 1793-1799
2-YEAR COMPARISON OF SAFETY AND EFFICACY OF ATORVASTATIN AND LOVASTATIN
Authors: BAKKERARKEMA RG SHURZINSKE L DAVIDSON M MCKENNEY J STEIN E SCHROTT H BLACK DM
Citation: Rg. Bakkerarkema et al., 2-YEAR COMPARISON OF SAFETY AND EFFICACY OF ATORVASTATIN AND LOVASTATIN, Atherosclerosis, 134(1-2), 1997, pp. 119-119
EFFECTIVENESS OF ATORVASTATIN IN TREATING PATIENTS TO LDL-C GOALS COMPARED WITH LOVASTATIN, PRAVASTATIN AND SIMVASTATIN
Authors: NAWROCKI J SHURZINSKE L BLACK DM
Citation: J. Nawrocki et al., EFFECTIVENESS OF ATORVASTATIN IN TREATING PATIENTS TO LDL-C GOALS COMPARED WITH LOVASTATIN, PRAVASTATIN AND SIMVASTATIN, Atherosclerosis, 134(1-2), 1997, pp. 120-120
EFFECT OF A NEW HMG-COA REDUCTASE INHIBITOR, ATORVASTATIN, ON LIPIDS,APOLIPOPROTEINS AND LIPOPROTEIN PARTICLES IN PATIENTS WITH ELEVATED SERUM-CHOLESTEROL AND TRIGLYCERIDE LEVELS
Authors: ALAUPOVIC P HEINONEN T SHURZINSKE L BLACK DM
Citation: P. Alaupovic et al., EFFECT OF A NEW HMG-COA REDUCTASE INHIBITOR, ATORVASTATIN, ON LIPIDS,APOLIPOPROTEINS AND LIPOPROTEIN PARTICLES IN PATIENTS WITH ELEVATED SERUM-CHOLESTEROL AND TRIGLYCERIDE LEVELS, Atherosclerosis, 133(1), 1997, pp. 123-133
THE LIPID-LOWERING EFFECTS OF ATORVASTATIN, A NEW HMG-COA REDUCTASE INHIBITOR - RESULTS OF A RANDOMIZED, DOUBLE-MASKED STUDY
Authors: HEINONEN TM STEIN E WEISS SR MCKENNEY JM DAVIDSON M SHURZINSKE L BLACK DM
Citation: Tm. Heinonen et al., THE LIPID-LOWERING EFFECTS OF ATORVASTATIN, A NEW HMG-COA REDUCTASE INHIBITOR - RESULTS OF A RANDOMIZED, DOUBLE-MASKED STUDY, Clinical therapeutics, 18(5), 1996, pp. 853-863
LP(A) LIPOPROTEIN AND IMPAIRED GLUCOSE-TOLERANCE - ASSOCIATION POORLYINVESTIGATED
Authors: UPRICHARD ACG SHURZINSKE L
Citation: Acg. Uprichard et L. Shurzinske, LP(A) LIPOPROTEIN AND IMPAIRED GLUCOSE-TOLERANCE - ASSOCIATION POORLYINVESTIGATED, BMJ. British medical journal, 308(6921), 1994, pp. 136-136
QUINAPRIL HYDROCHLORIDE EFFECTS ON RENAL-FUNCTION IN PATIENTS WITH RENAL DYSFUNCTION AND HYPERTENSION - A DRUG-WITHDRAWAL STUDY
Authors: MILLER MA TEXTER M GMEREK A ROBBINS J SHURZINSKE L CANTER D
Citation: Ma. Miller et al., QUINAPRIL HYDROCHLORIDE EFFECTS ON RENAL-FUNCTION IN PATIENTS WITH RENAL DYSFUNCTION AND HYPERTENSION - A DRUG-WITHDRAWAL STUDY, Cardiovascular drugs and therapy, 8(2), 1994, pp. 271-275
Risultati: 1-8 |